Skip to the page

Data / Drug companies / Ohm Laboratories Inc.

Ohm Laboratories Inc.: 38 products in the FDA NDC directory, labeler code 51660

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Ohm Laboratories Inc. (labeler code 51660) lists 38 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 31 over the counter drugs, 5 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.

The request: Watch Ohm Laboratories Inc. (FDA labeler code 51660): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
51660
Products in commercial distribution
38
Packages
85
Finished drugs by generic name
18
Prescription products
5
Over the counter products
31
Flagged as original packager
31 of 31 products that carry the flag
Started marketing in the last 12 months
3
Earliest marketing start
February 1, 1993
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)3694.7%
Drugs for further processing25.3%

Products by type

TypeProductsShare
Over the counter drugs3181.6%
Prescription drugs513.2%
Drugs for further processing25.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1128.9%
Tablet, extended release923.7%
Tablet, film coated615.8%
Tablet, chewable615.8%
Tablet, film coated, extended release25.3%
Capsule, delayed release12.6%
Tablet, sugar coated12.6%
Tablet, orally disintegrating12.6%
Tablet, delayed release12.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
My After Plan51660-098TabletGeneric drugs (ANDA)September 1, 2026
My Choice51660-096TabletGeneric drugs (ANDA)May 1, 2026
Dye-free loratadine51660-755Tablet, chewableGeneric drugs (ANDA)December 2, 2025
Cetirizine hydrochloride51660-939TabletDrugs for further processingNovember 28, 2024
Loratadine51660-526TabletDrugs for further processingNovember 28, 2024
Dye-free childrens loratadine51660-726Tablet, chewableGeneric drugs (ANDA)March 15, 2024
Cetirizine Hydrochloride51660-066Tablet, chewableGeneric drugs (ANDA)July 21, 2022
Fexofenadine hydrochloride51660-998Tablet, film coatedGeneric drugs (ANDA)April 29, 2022
Guaifenesin51660-567Tablet, extended releaseGeneric drugs (ANDA)April 1, 2022
Guaifenesin51660-566Tablet, extended releaseGeneric drugs (ANDA)April 1, 2022
Loperamide HCl and Simethicone51660-069TabletGeneric drugs (ANDA)January 13, 2022
Guaifenesin and Dextromethorphan HBr51660-301Tablet, extended releaseGeneric drugs (ANDA)July 1, 2021
Guaifenesin and Dextromethorphan HBr51660-110Tablet, extended releaseGeneric drugs (ANDA)July 1, 2021
Guaifenesin and Pseudoephedrine HCl51660-077Tablet, extended releaseGeneric drugs (ANDA)April 1, 2021
Guaifenesin and Pseudoephedrine HCl51660-074Tablet, extended releaseGeneric drugs (ANDA)April 1, 2021
Dye-Free Childrens Loratadine51660-112Tablet, chewableGeneric drugs (ANDA)August 19, 2020
Esomeprazole51660-027Capsule, delayed releaseGeneric drugs (ANDA)August 14, 2020
Omeprazole51660-029Tablet, delayed releaseGeneric drugs (ANDA)June 1, 2019
Childrens Loratadine51660-754Tablet, chewableGeneric drugs (ANDA)June 30, 2018
Loratadine51660-753Tablet, chewableGeneric drugs (ANDA)June 1, 2018
Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride51660-037Tablet, film coated, extended releaseGeneric drugs (ANDA)March 1, 2018
Levonorgestrel51660-999TabletGeneric drugs (ANDA)November 1, 2017
Levonorgestrel51660-723TabletGeneric drugs (ANDA)November 1, 2017
Loratadine Allergy Relief51660-526TabletGeneric drugs (ANDA)November 1, 2017
Ezetimibe51660-200TabletGeneric drugs (ANDA)June 12, 2017

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.